InflaRx N.V. (IFRX)

Market Closed

12 Dec, 20:00

NASDAQ (NGS)

1. 05

+0.03

+2.94%

80.62M Market Cap

- P/E Ratio

0% Div Yield

537,159 Volume

- Eps

$ 1.02

Previous Close

Day Range

1.03 1.08

Year Range

0.71 2.77

Want to track IFRX and more in your Portfolio? 🎯

Get Started For Free

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate.

Zacks | 4 months ago

InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks | 8 months ago

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.

Zacks | 11 months ago

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.27.

Zacks | 1 year ago

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

InflaRx N.V. (IFRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21.

Zacks | 1 year ago

Affiliate Program About Terms Privacy Help Contact Us